Top

Published in:

01-12-2016 | Original Article

VEGF-activated miR-144 regulates autophagic survival of prostate cancer cells against Cisplatin

Authors: Feng Liu, Jihong Wang, Qiang Fu, Xinru Zhang, Ying Wang, Jialin Liu, Jianwen Huang, Xiangguo Lv

Published in: Tumor Biology | Issue 12/2016

Abstract

Cisplatin is a commonly used chemotherapy drug for prostate cancer (PC). However, some PCs are resistant to cisplatin treatment, while the molecular mechanisms underlying the resistance of PCs to cisplatin are not completely understood. In this study, we found that cisplatin dose-dependently activated Beclin-1 in two PC cell lines, PC3 and LNCap. Autophagy suppression significantly increased the cisplatin-induced cell death of these PC cells in a CCK-8 assay. Moreover, microRNA (miR)-144 levels were significantly downregulated in cisplatin-treated PC cells, in a VEGF-dependent manner. Bioinformatics analysis showed that miR-144 targeted the 3′-UTR of Beclin-1 mRNA to inhibit its translation, which was confirmed by luciferase reporter assay. In PC patients after cisplatin treatment, low miR-144 levels appeared to predict poor outcome of patients’ survival. Together, these data suggest that cisplatin may induce VEGF to suppress miR-144 levels in PC cells, which subsequently upregulates Beclin-1 to increase autophagic cell survival against cisplatin-induced cell death. Upregulation of miR-144 or suppression of cell autophagy may improve the outcome of cisplatin therapy in PC.

Saylor PJ. Prostate cancer: the androgen receptor remains front and centre. Nat Rev Clin Oncol. 2013;10:126–8.CrossRefPubMed

Alva A, Hussain M. The changing natural history of metastatic prostate cancer. Cancer J. 2013;19:19–24.CrossRefPubMed

Beltran H, Rubin MA. New strategies in prostate cancer: Translating genomics into the clinic. Clin Cancer Res. 2013;19:517–23.CrossRefPubMed

Xin L. Cells of origin for cancer: an updated view from prostate cancer. Oncogene. 2013;32:3655–63.CrossRefPubMed

Huang S, Liao Q, Li L, Xin D. Pttg1 inhibits smad3 in prostate cancer cells to promote their proliferation. Tumour Biol. 2014;35:6265–70.CrossRefPubMed

Xia Q, Li C, Bian P, Wang J, Dong S. Targeting smad3 for inhibiting prostate cancer metastasis. Tumour Biol. 2014;35:8537–41.CrossRefPubMed

Lin R, Feng J, Dong S, Pan R, Zhuang H, Ding Z. Regulation of autophagy of prostate cancer cells by beta-catenin signaling. Cell Physiol Biochem. 2015;35:926–32.CrossRefPubMed

Li T, Zhao X, Mo Z, Huang W, Yan H, Ling Z, et al. Formononetin promotes cell cycle arrest via downregulation of akt/cyclin d1/cdk4 in human prostate cancer cells. Cell Physiol Biochem. 2014;34:1351–8.CrossRefPubMed

Gillies K, Wertman J, Charette N, Dupre DJ. Anterograde trafficking of cxcr4 and ccr2 receptors in a prostate cancer cell line. Cell Physiol Biochem. 2013;32:74–85.CrossRefPubMed

10.

Dhar S, Kolishetti N, Lippard SJ, Farokhzad OC. Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo. Proc Natl Acad Sci U S A. 2011;108:1850–5.CrossRefPubMedPubMedCentral

11.

Villar J, Quadri HS, Song I, Tomita Y, Tirado OM, Notario V. Pcph/entpd5 expression confers to prostate cancer cells resistance against cisplatin-induced apoptosis through protein kinase calpha-mediated bcl-2 stabilization. Cancer Res. 2009;69:102–10.CrossRefPubMedPubMedCentral

12.

Dhar S, Gu FX, Langer R, Farokhzad OC, Lippard SJ. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized pt(iv) prodrug-plga-peg nanoparticles. Proc Natl Acad Sci U S A. 2008;105:17356–61.CrossRefPubMedPubMedCentral

13.

Green DR, Levine B. To be or not to be? How selective autophagy and cell death govern cell fate. Cell. 2014;157:65–75.CrossRefPubMedPubMedCentral

14.

Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell. 2008;132:27–42.CrossRefPubMedPubMedCentral

15.

Guo JY, Xia B, White E. Autophagy-mediated tumor promotion. Cell. 2013;155:1216–9.CrossRefPubMedPubMedCentral

16.

White E. Deconvoluting the context-dependent role for autophagy in cancer. Nat Rev Cancer. 2012;12:401–10.CrossRefPubMedPubMedCentral

17.

Huang CY, Huang SP, Lin VC, Yu CC, Chang TY, Lu TL, et al. Genetic variants of the autophagy pathway as prognostic indicators for prostate cancer. Sci Rep. 2015;5:14045.CrossRefPubMedPubMedCentral

18.

Farrow JM, Yang JC, Evans CP. Autophagy as a modulator and target in prostate cancer. Nat Rev Urol. 2014;11:508–16.CrossRefPubMedPubMedCentral

19.

Shi Y, Han JJ, Tennakoon JB, Mehta FF, Merchant FA, Burns AR, et al. Androgens promote prostate cancer cell growth through induction of autophagy. Mol Endocrinol. 2013;27:280–95.CrossRefPubMed

20.

Ouyang DY, Xu LH, He XH, Zhang YT, Zeng LH, Cai JY, et al. Autophagy is differentially induced in prostate cancer lncap, du145 and pc-3 cells via distinct splicing profiles of atg5. Autophagy. 2013;9:20–32.CrossRefPubMedPubMedCentral

21.

Lian J, Karnak D, Xu L. The bcl-2-beclin 1 interaction in (−)-gossypol-induced autophagy versus apoptosis in prostate cancer cells. Autophagy. 2010;6:1201–3.CrossRefPubMedPubMedCentral

22.

Lamoureux F, Zoubeidi A. Dual inhibition of autophagy and the akt pathway in prostate cancer. Autophagy. 2013;9:1119–20.CrossRefPubMedPubMedCentral

23.

Eichmann A, Simons M. Vegf signaling inside vascular endothelial cells and beyond. Curr Opin Cell Biol. 2012;24:188–93.CrossRefPubMedPubMedCentral

24.

Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473:298–307.CrossRefPubMedPubMedCentral

25.

Ferrara N, Gerber HP, LeCouter J. The biology of vegf and its receptors. Nat Med. 2003;9:669–76.CrossRefPubMed

26.

Xiao X, Prasadan K, Guo P, El-Gohary Y, Fischbach S, Wiersch J, et al. Pancreatic duct cells as a source of vegf in mice. Diabetologia. 2014;57:991–1000.CrossRefPubMedPubMedCentral

27.

Xiao X, Guo P, Chen Z, El-Gohary Y, Wiersch J, Gaffar I, et al. Hypoglycemia reduces vascular endothelial growth factor a production by pancreatic beta cells as a regulator of beta cell mass. J Biol Chem. 2013;288:8636–46.CrossRefPubMedPubMedCentral

28.

Bagri A, Kouros-Mehr H, Leong KG, Plowman GD. Use of anti-vegf adjuvant therapy in cancer: Challenges and rationale. Trends Mol Med. 2010;16:122–32.CrossRefPubMed

29.

Inai T, Mancuso M, Hashizume H, Baffert F, Haskell A, Baluk P, et al. Inhibition of vascular endothelial growth factor (vegf) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol. 2004;165:35–52.CrossRefPubMedPubMedCentral

30.

Shima DT, Adamis AP, Ferrara N, Yeo KT, Yeo TK, Allende R, et al. Hypoxic induction of endothelial cell growth factors in retinal cells: Identification and characterization of vascular endothelial growth factor (vegf) as the mitogen. Mol Med. 1995;1:182–93.PubMedPubMedCentral

31.

Cheng SY, Nagane M, Huang HS, Cavenee WK. Intracerebral tumor-associated hemorrhage caused by overexpression of the vascular endothelial growth factor isoforms vegf121 and vegf165 but not vegf189. Proc Natl Acad Sci U S A. 1997;94:12081–7.CrossRefPubMedPubMedCentral

32.

Huez I, Creancier L, Audigier S, Gensac MC, Prats AC, Prats H. Two independent internal ribosome entry sites are involved in translation initiation of vascular endothelial growth factor mRNA. Mol Cell Biol. 1998;18:6178–90.CrossRefPubMedPubMedCentral

33.

Di Leva G, Croce CM. Mirna profiling of cancer. Curr Opin Genet Dev. 2013;23:3–11.CrossRefPubMedPubMedCentral

34.

Pereira DM, Rodrigues PM, Borralho PM, Rodrigues CM. Delivering the promise of miRNA cancer therapeutics. Drug Discov Today. 2013;18:282–9.CrossRefPubMed

35.

Mei Q, Li F, Quan H, Liu Y, Xu H. Busulfan inhibits growth of human osteosarcoma through mir-200 family microRNAs in vitro and in vivo. Cancer Sci. 2014;105:755–62.CrossRefPubMedPubMedCentral

36.

Wang F, Xiao W, Sun J, Han D, Zhu Y. Mirna-181c inhibits egfr-signaling-dependent mmp9 activation via suppressing akt phosphorylation in glioblastoma. Tumour Biol. 2014;35:8653–8.CrossRefPubMed

37.

Liu G, Jiang C, Li D, Wang R, Wang W. Mirna-34a inhibits egfr-signaling-dependent mmp7 activation in gastric cancer. Tumour Biol. 2014;35:9801–6.CrossRefPubMed

38.

Zhao M, Huang J, Gui K, Xiong M, Cai G, Xu J, et al. The downregulation of mir-144 is associated with the growth and invasion of osteosarcoma cells through the regulation of tagln expression. Int J Mol Med. 2014;34:1565–72.PubMed

39.

Cao T, Li H, Hu Y, Ma D, Cai X. Mir-144 suppresses the proliferation and metastasis of hepatocellular carcinoma by targeting e2f3. Tumour Biol. 2014;35:10759–64.CrossRefPubMed

40.

Zha W, Cao L, Shen Y, Huang M. Roles of mir-144-zfx pathway in growth regulation of non-small-cell lung cancer. PLoS One. 2013;8, e74175.CrossRefPubMedPubMedCentral

41.

Hassan F, Nuovo GJ, Crawford M, Boyaka PN, Kirkby S, Nana-Sinkam SP, et al. Mir-101 and mir-144 regulate the expression of the cftr chloride channel in the lung. PLoS One. 2012;7, e50837.CrossRefPubMedPubMedCentral

42.

Iwaya T, Yokobori T, Nishida N, Kogo R, Sudo T, Tanaka F, et al. Downregulation of mir-144 is associated with colorectal cancer progression via activation of mtor signaling pathway. Carcinogenesis. 2012;33:2391–7.CrossRefPubMed

43.

Akiyoshi S, Fukagawa T, Ueo H, Ishibashi M, Takahashi Y, Fabbri M, et al. Clinical significance of mir-144-zfx axis in disseminated tumour cells in bone marrow in gastric cancer cases. Br J Cancer. 2012;107:1345–53.CrossRefPubMedPubMedCentral

44.

Kalimutho M, Del Vecchio Blanco G, Di Cecilia S, Sileri P, Cretella M, Pallone F, et al. Differential expression of mir-144* as a novel fecal-based diagnostic marker for colorectal cancer. J Gastroenterol. 2011;46:1391–402.CrossRefPubMed

45.

Huang SQ, Liao QJ, Wang XW, Xin DQ, Chen SX, Wu QJ, et al. Rnai-mediated knockdown of pituitary tumor- transforming gene-1 (pttg1) suppresses the proliferation and invasive potential of pc3 human prostate cancer cells. Braz J Med Biol Res. 2012;45:995–1001.CrossRefPubMedPubMedCentral

46.

Horoszewicz JS, Leong SS, Carter WA. Differential susceptibility of spleen focus-forming virus and murine leukemia viruses to ansamycin antibiotics. Antimicrob Agents Chemother. 1977;12:4–10.CrossRefPubMedPubMedCentral

47.

Coronnello C, Benos PV. Comir: Combinatorial microRNA target prediction tool. Nucleic Acids Res. 2013;41:W159–64.CrossRefPubMedPubMedCentral

Title: VEGF-activated miR-144 regulates autophagic survival of prostate cancer cells against Cisplatin
Authors: Feng Liu
Jihong Wang
Qiang Fu
Xinru Zhang
Ying Wang
Jialin Liu
Jianwen Huang
Xiangguo Lv
Publication date: 01-12-2016
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 12/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-015-4383-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2016

Hedgehog/Gli1 signal pathway facilitates proliferation, invasion, and migration of cutaneous SCC through regulating VEGF

miR-122 inhibits cancer cell malignancy by targeting PKM2 in gallbladder carcinoma

Notch3 negatively regulates chemoresistance in breast cancers

Retraction Note to: Downregulation of miR-148b as biomarker for early detection of hepatocellular carcinoma and may serve as a prognostic marker

Downregulation of ARHGDIA contributes to human glioma progression through activation of Rho GTPase signaling pathway

Regulation of exosomes released from normal ovarian epithelial cells and ovarian cancer cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer